Tag:

Europe

Latest Headlines

Latest Headlines

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Novo Nordisk wins EU approval for a diabetes combo with billion-dollar potential

Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.

Dutch VC opens €65M cancer fund, Affimed IPO falls short, Evotec begins legal action

In this week's EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. And more.

More counterfeits of Roche cancer drugs surface in Europe

Counterfeiters in Europe are displaying a fondness for mimicking high-priced Roche cancer drugs. For the second time in 5 months, authorities there have uncovered fakes, and the two cases appear not to be connected.

Hunt for next Sovaldi leads to $150M deal, Poxel raises €10M, AbbVie backs AM-Pharma round

In this week's EuroBiotech Report, the search for the drug that can do to hepatitis B what Sovaldi does to hepatitis C led OnCure BioPharma to Sweden to strike a $150 million (€116 million) deal with NeuroVive Pharmaceutical. And more.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.

EU creates €1B fund for research on the use of graphene

The European Union is betting heavily on graphene, a potential material of the future with several med tech applications, via a €1 billion ($1.3 billion) research fund dubbed the Graphene Flagship.

AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015

In this week's EuroBiotech Report, having spent much of 2014 touting the potential of its clinical-stage oncology candidates, AstraZeneca struck a deal with Redx Pharma to work on the next generation of cancer drugs. And more.

Sources: West Pharmaceutical looks at $130M investment in Ireland

Pennsylvania-based West Pharmaceutical is again looking east for expansion. The maker of glass products for the pharma biz, which recently opened a plant in India, is now looking at adding a facility in Ireland that could run to €100 million.

Bayer's startup accelerator funds 5 device, healthcare app companies

Fresh off the sales of its interventional device unit to Boston Scientific, Bayer Healthcare is showing renewed interest in med tech via its startup accelerator.